Home » FDA Approves GSK's Vaccine for Adolescents Against Pertussis
FDA Approves GSK's Vaccine for Adolescents Against Pertussis
The FDA has approved GlaxoSmithKline's booster vaccine, Boostrix.
Boostrix [Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed (Tdap)] is indicated to be given as a single dose to individuals aged 10 to 18 years thereby adding a pertussis component to the routine tetanus/diphtheria booster currently administered to teens.
Previously, there was no pertussis vaccine approved for use in the U.S. in children 7 years of age or older. Immunity from childhood vaccination generally begins to wear off after five to 10 years, leaving many adolescents susceptible to this highly contagious disease.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May